Glucocorticoids
ATC code: H02AB06 (Prednisolone)
Binds intracellular glucocorticoid receptors, suppressing inflammatory and immune responses at multiple levels – inhibits transcription of pro-inflammatory cytokines, reduces leukocyte migration, and suppresses phospholipase A2 activity. Intermediate potency: 4 times more potent than hydrocortisone but weaker than dexamethasone. Duration of action 12-36 hours.
First line
A short course of systemic corticosteroids (5-7 days) is the standard of care for moderate-to-severe asthma exacerbations per . Prednisolone 40-50 mg daily in adults, 1-2 mg/kg in children. Start as early as possible during an exacerbation. Long-term systemic corticosteroid therapy for asthma is reserved for severe uncontrolled disease after all inhaled options are exhausted.
First line
Core drug for autoimmune disease flares – SLE, rheumatoid arthritis, vasculitis, autoimmune hepatitis. Acute situations require high doses (1 mg/kg daily) with subsequent gradual tapering. The goal is the lowest maintenance dose or full discontinuation to minimize cumulative toxicity.
First line
In anaphylaxis, epinephrine is first-line. Prednisolone is given as an adjunct to prevent biphasic reactions and suppress the late-phase allergic response. In severe drug reactions – Stevens-Johnson syndrome, serum sickness – it is used at high doses.
First line
In patients with COVID-19 and hypoxaemia or critical illness, corticosteroids reduce mortality. The RECOVERY trial (NEJM 2021, 6,425 participants) showed dexamethasone 6 mg daily for 10 days reduced mortality by 17 % on oxygen therapy and by 35 % on mechanical ventilation. Prednisolone 40–50 mg daily is used as the dexamethasone 6 mg equivalent (anti-inflammatory potency ratio 1:7). Living Guidelines and Russian Ministry of Health guidelines classify systemic corticosteroids as a strong recommendation for severe and critical disease. In outpatients without hypoxaemia, there is no benefit and potential harm: increased risk of secondary infections and delayed viral clearance.
Use is restricted to hospital setting and a specific group – patients with hypoxaemia (SpO2 below 94 %) or on mechanical ventilation. In outpatients with mild-to-moderate disease, glucocorticoids are not appropriate.
Not recommended
Corticosteroids for "getting back on one's feet," chronic fatigue, subjective weakness, or asthenia are not supported by any international guideline. Short-term improvement on prednisolone is the drug's euphoric effect, not treatment of a cause. Upon discontinuation, state worsens below baseline due to withdrawal syndrome. Prolonged use produces cumulative complications: osteoporosis, steroid-induced diabetes, Cushing syndrome, adrenal insufficiency. Chronic fatigue requires differential workup: anaemia, B12 deficiency, hypothyroidism, depression, chronic infections – treat the cause.
Not recommended
Prednisolone and other systemic corticosteroids are not used for acute viral upper respiratory infections in any international guideline (, , , CDC, BMJ Best Practice). A viral infection without bacterial complication resolves in 5–10 days on its own. Systemic corticosteroids do not suppress the virus; they suppress the immune response and prolong viral shedding. Self-prescribed prednisolone «to recover faster» carries risks of secondary bacterial infections, hyperglycaemia, ulcer complications, and withdrawal syndrome on abrupt discontinuation.
Not recommended
Prednisolone for muscle gain reflects a fitness-community confusion between glucocorticoids and anabolic-androgenic steroids. These are entirely different drug classes. Glucocorticoids (prednisolone, dexamethasone, hydrocortisone) act on muscle catabolically: they break down muscle protein, induce steroid myopathy, and cause weakness predominantly in proximal groups. Anabolic muscle action belongs to testosterone, nandrolone, and other AAS – separate drugs with their own risks. Prednisolone for «bulking» produces the opposite: loss of muscle strength, fat mass gain, and Cushingoid fat redistribution.
FDA category C (prednisone/prednisolone). Use in pregnancy when benefit outweighs risk. Prednisolone is partially inactivated by placental 11-beta-HSD, so less reaches the fetus compared to dexamethasone. Prolonged high-dose use carries risk of cleft palate and neonatal adrenal insufficiency.
Passes into breast milk. At doses up to 20 mg daily, the amount reaching the infant is minimal. A 4-hour gap between dosing and nursing is recommended at higher doses.
prednisolone is evaluated for the following indications with varying evidence strength: Asthma (evidence tier A), Autoimmune conditions (evidence tier A), Severe allergic reactions (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of prednisolone (≥ 1 in 100): Increased appetite and weight gain, Insomnia, irritability, mood swings, Fluid retention, edema, Hyperglycemia, Dyspepsia, increased gastric acidity. See the Safety section for uncommon and serious reactions.
FDA category C. FDA category C (prednisone/prednisolone). Use in pregnancy when benefit outweighs risk. Prednisolone is partially inactivated by placental 11-beta-HSD, so less reaches the fetus compared to dexamethasone. Prolonged high-dose use carries risk of cleft palate and neonatal adrenal insufficiency.
Passes into breast milk. At doses up to 20 mg daily, the amount reaching the infant is minimal. A 4-hour gap between dosing and nursing is recommended at higher doses.
prednisolone is contraindicated in: Systemic fungal infections; Hypersensitivity to prednisolone; Live vaccine administration at immunosuppressive doses. Full list in the Safety section.
no international guideline supports corticosteroids for uncomplicated viral infection. Prednisolone suppresses the immune response, prolongs viral shedding, and raises the risk of secondary bacterial infection. A cold resolves in 5–10 days on its own.
corticosteroids do lower temperature through anti-inflammatory action. But this masks a symptom, not its cause. In viral infection, fever is part of the immune response; treat it with paracetamol or ibuprofen as needed, not with systemic corticosteroids. Frequent use for fever is a gateway to steroid dependence.
this reflects confusion between glucocorticoids (prednisolone, dexamethasone) and anabolic steroids (testosterone, nandrolone). Glucocorticoids are catabolic for muscle – they break down protein, cause myopathy, and weakness. Prednisolone for «bulking» produces the opposite effect.
the euphoric effect of corticosteroids gives subjective improvement in the first days but does not treat fatigue's cause. On withdrawal, symptoms worsen – a direct path to steroid dependence on repeated courses.
corticosteroids for severe allergic reactions are used as short, one-time therapy. Chronic self-administration for itch, allergic rhinitis, or urticaria leads to steroid dermatitis, tachyphylaxis, and rebound flares on discontinuation.
the opposite extreme. In autoimmune flares, anaphylaxis, severe COVID-19 with hypoxia, or asthma exacerbation, corticosteroids save lives – high-evidence indications. Principled refusal is as dangerous as self-prescribing without indication.